1European Association for Cardiovascular Prevention&Rehabilitation,Reiner Z,Catapano AL,et al.ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and the European Atherosclerosis Society(EAS)[J].Eur Heart J,2011,32(14):1769-1818.
2Carter AA,Gomes T,Camacho X,et al.Risk of incident diabetes among patients treated with statins:population based study[J].BMJ,2013,346:f2610.
3Mancini GB,Tashakkor AY,Baker S,et al.Diagnosis,prevention,and management of statin adverse effects and intolerance:Canadian Working Group Consensus update[J].Can J Cardiol,2013,29(12):1553-1568.
5Cohen JD,Brinton EA,Ito MK,et al.Understanding statin use in America and gaps in patient education(USAGE):an internet-based survey of 10138 current and former statin users[J].J Clin Lipidol,2012,6(3):208-215.
6Zhang H,Plutzky J,Skentzos S,et al.Discontinuation of statins in routine care settings:a cohort study[J].Ann Int Med,2013,158(7):526-534.
7El-Salem K,Ababeneh B,Rudnicki S,et al.Prevalence and risk factors of muscle complications secondary to statins[J].Muscle Nerve,2011,44(6):877-881.
8Chowdhury R,Khan H,Heydon E,et al.Adherence to cardiovascular therapy:a meta-analysis of prevalence and clinical consequences[J].Eur Heart J,2013,34(38):2940-2948.
9Ganga HV,Slim HB,Thompson PD.A systematic review of statininduced muscle problems in clinical trials[J].Am Heart J,2014,168(1):6-15.
10Finegold JA,Manisty CH,Goldacre B,et al.What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug?Systematic review of randomized placebocontrolled trials to aid individual patient choice[J].Eur J Prev Cardiol,2014,21(4):464-476.
